MAP2K7 and lung cancer: Our results provide a strong rationale for combining current chemo and anti-MEK cancer drugs with inhibitors of the HSP90/AXL/eIF4E/UPR pathway to treat KRAS-mutant lung cancer and perhaps other malignancies for which no effective therapy available for advanced diseases.